Latest News - Page 6

Study Finds Link between Hepatitis C and Parkinson's Disease
BY BILL SCHU
Study is the first to demonstrate a strong association between HCV and PD.
Doctor Behind Development of Sofosbuvir Comes Under Scrutiny
BY BILL SCHU
Report finds Gilead Sciences charged more for Sovaldi and Harvoni than required to recoup acquisition costs, clinical research, and marketing expenditures.
Q&A with AbbVie's Barry Bernstein, MD: Are More FDA Warnings in the Works?
BY GALE SCOTT
Latest developments in hepatitis C drug development.
Insurance Lagging on Paying for HCV Antivirals
BY GALE SCOTT
Medicaid patients face a hepatitis C drug refusal rate of 46%.
Tasmanian Physicians Find Less Expensive Route to Obtaining Hepatitis C Medications
BY BILL SCHU
Stakeholders look for creative ways to get around the high cost of drugs to treat the hepatitis C virus.
Drug Review: Daklinza for Chronic Hepatitis C Infection
BY JEFFREY BURGESS, PHARMD CANDIDATE 2016; JERICA SINGLETON, PHARMD CANDIDATE 2016; AND JACLYN D. COLE, PHARMD, BCPS
An overview of Daklinza (daclatasvir) for hepatitis C treatment.
HCV in Egypt: Success in Treating Genotype 4
BY GALE SCOTT
Researchers conduct the largest interferon-free clinical trial in HCV-GT4 patients.
Nonalcoholic Fatty Liver Disease and Eating Habits: Slow Down!
BY JEANNETTE Y. WICK, RPH, MBA, FASCP
Eating before bed can have a significant impact on the development of nonalcoholic fatty liver disease.
$auto_registration$